全文获取类型
收费全文 | 2003篇 |
免费 | 131篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 133篇 |
妇产科学 | 31篇 |
基础医学 | 217篇 |
口腔科学 | 41篇 |
临床医学 | 250篇 |
内科学 | 397篇 |
皮肤病学 | 20篇 |
神经病学 | 112篇 |
特种医学 | 243篇 |
外科学 | 199篇 |
综合类 | 47篇 |
一般理论 | 1篇 |
预防医学 | 156篇 |
眼科学 | 16篇 |
药学 | 97篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 168篇 |
出版年
2021年 | 19篇 |
2020年 | 17篇 |
2019年 | 19篇 |
2018年 | 22篇 |
2017年 | 26篇 |
2016年 | 18篇 |
2015年 | 31篇 |
2014年 | 39篇 |
2013年 | 52篇 |
2012年 | 76篇 |
2011年 | 66篇 |
2010年 | 70篇 |
2009年 | 78篇 |
2008年 | 74篇 |
2007年 | 64篇 |
2006年 | 67篇 |
2005年 | 57篇 |
2004年 | 54篇 |
2003年 | 55篇 |
2002年 | 46篇 |
2001年 | 44篇 |
2000年 | 46篇 |
1999年 | 50篇 |
1998年 | 92篇 |
1997年 | 88篇 |
1996年 | 97篇 |
1995年 | 63篇 |
1994年 | 58篇 |
1993年 | 51篇 |
1992年 | 46篇 |
1991年 | 48篇 |
1990年 | 40篇 |
1989年 | 62篇 |
1988年 | 50篇 |
1987年 | 59篇 |
1986年 | 33篇 |
1985年 | 39篇 |
1984年 | 32篇 |
1983年 | 28篇 |
1982年 | 18篇 |
1981年 | 18篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 13篇 |
1977年 | 13篇 |
1976年 | 16篇 |
1975年 | 9篇 |
1974年 | 6篇 |
1972年 | 8篇 |
1967年 | 6篇 |
排序方式: 共有2148条查询结果,搜索用时 15 毫秒
1.
PJ Commerford 《Cardiovascular journal of Africa》2015,26(4):151-Aug;26(4):151
2.
G M Novotny 《The Journal of otolaryngology》1989,18(7):354-356
In 17 cases the author has removed intraglandular submandibular calculi by an oral route utilizing blunt soft tissue dissection after an incision of the mucosa only. General anesthesia is used and the patient discharged after an overnight stay. No complications were encountered. All patients were back on full diet in 48 hours. 相似文献
3.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
4.
5.
Hans Bosma Martin PJ van Boxtel Gertrudis IJM Kempen Jacques ThM van Eijk Jelle Jolles 《BMC public health》2007,7(1):179
Background
The aims of this study were to examine the extent to which higher intellectual abilities protect higher socio-economic groups from functional decline and to examine whether the contribution of intellectual abilities is independent of childhood deprivation and low birth weight and other socio-economic and developmental factors in early life. 相似文献6.
7.
8.
Localized 1H NMR spectra of glutamate in the human brain. 总被引:2,自引:0,他引:2
D L Rothman C C Hanstock O A Petroff E J Novotny J W Prichard R G Shulman 《Magnetic resonance in medicine》1992,25(1):94-106
Localized 1H NMR spectra at TE = 12 ms were obtained from cerebral cortex of human subjects using ISIS with surface suppression. The 2.29-ppm resonance was assigned to C4 glutamate with contributions from C4 glutamine and GABA using in vivo spectral editing and comparison of chemical shift with pure compounds. The measured intensity ratio between the 2.29 resonance and the creatine resonance at 3.03 ppm was in good agreement with the ratio predicted from previously reported measurements of glutamate, glutamine, and GABA concentrations in biopsied human brain tissue. 相似文献
9.
Previous reports in the literature have described correlation of increasing repeat length with severity of the phenotype, in Kennedy syndrome. We describe male siblings with different repeat lengths, with lack of expression of the phenotype in the sibling with the longer repeat length. The phenotype was identical to motor neurone disease. There is variability of expression in Kennedy syndrome and repeat length even in siblings cannot be taken as a conclusive indicator of severity. CAG repeat length cannot be used to predict the natural history of Kennedy disease. The diagnosis of Kennedy syndrome should be considered in male patients presenting with atypical motor neurone disease. 相似文献
10.
PJ Woll PhD MRCP R Pettengell PhD FRACP 《International journal of clinical practice》1997,51(2):111-115
SUMMARY The interferons are natural glycoproteins secreted in response to various stimuli, including viral infection. They have antiviral, antiproliferative and immunomodulatory effects on different target cell populations. Since recombinant human interferons have become available, they have been tested in a wide range of malignancies. They are well established in the treatment of hairy cell leukaemia, chronic myelogenous leukaemia and multiple myeloma. Although they have documented activity against lymphoma, melanoma, renal cell cancer and carcinoid tumours, their role in the treatment of these tumours is less clear. In the common solid tumours, such as lung cancer and colorectal cancer, the use of interferons remains experimental. Here we will summarise their practice applications in oncology, using randomised studies where available to establish their place in multi-modality treatment. We will not discuss their use as antiviral or immunomodulating agents in viral and autoimmune diseases, multiple sclerosis or after organ transplantation. 相似文献